COMP <GO>
CVS vs PEP // NET PROFIT MARGIN
CVS Health Corporation (NYSE) VS. PepsiCo Inc. (NASDAQ) • 15-METRIC TALLY: CVS 3
— PEP 11
▲ NET PROFIT MARGIN LEADER: PEP
LAST: $90.25 (-0.09%) • MKT CAP: $115.53B
net-margins
0.40%
LAST: $137.34 (+2.65%) • MKT CAP: $182.32B
net-margins
8.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CVS VS. PEP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CVS | PEP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.00% | 54.10% | -9.10 | PEP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.60% | 17.00% | -14.40 | PEP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.7x | 14.3x | +11.40 | PEP | /valuation <GO> |
| Free Cash Flow Yield | 6.76% | 4.31% | +2.45 | CVS | /fcf-yield <GO> |
| Operating Margin | 1.20% | 12.20% | -11.00 | PEP | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 0.40% | 8.80% | -8.40 | PEP | /net-margins <GO> |
| Revenue Growth (YoY) | 7.80% | 2.30% | +5.50 | CVS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.94% | 4.19% | -1.25 | PEP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.31 | 3.38 | -1.07 | PEP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | CVS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.50% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.5 | 61.1 | -13.60 | PEP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.89 | -0.01 | PEP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 60.7x | 20.6x | +40.10 | PEP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $115.53B | $182.32B | -$66.79B | PEP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CVS REV | PEP REV | CVS GROSS % | PEP GROSS % | CVS FCF | PEP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $402.07B | $93.92B | 45.0% | 54.1% | $7.81B | $7.86B |
| FY 2024 | $372.81B | $91.85B | 44.7% | 54.6% | $6.33B | $8.37B |
| FY 2023 | $357.78B | $91.47B | 44.0% | 44.0% | -$2.67B | $9.33B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CVS // BETA 0.88
PEP // BETA 0.89